诺和诺德在减肥药市场的发展,或是商业史上最具讽刺意味的“先发劣势”案例之一。 2023年,凭借Ozempic和Wegovy的火爆需求,诺和诺德一度成为欧洲市值最高的公司,甚至超越了奢侈品巨头LVMH。然而如今,这家公司在短短一年内股价暴跌超过50%,CEO被迫下台,市场份额不断流失,被美国竞争对手礼来后来居上。 面对激增的市场需求,诺和诺德不仅低估预期导致供应短缺,而且并未抓紧扩产,反而选择了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.